What LDL‑C level should be targeted in patients with established coronary artery disease?

LDL-C Goal in Established Coronary Artery Disease

For patients with established coronary artery disease, the target LDL-C is <55 mg/dL (<1.4 mmol/L) with at least a 50% reduction from baseline. 1, 2, 3

Evidence Basis for the <55 mg/dL Target

• The 2024 ESC guidelines for chronic coronary syndromes establish LDL-C <55 mg/dL as a Class I, Level A recommendation for all patients with established CAD, representing the most aggressive evidence-based target. 1, 3

• The 2025 ACC/AHA guidelines similarly mandate an LDL-C goal of <55 mg/dL for all post-ACS patients, marking a shift from the older <70 mg/dL threshold used in earlier secondary prevention recommendations. 2

• Each 1.0 mmol/L (~39 mg/dL) reduction in LDL-C produces approximately 20-25% relative reduction in cardiovascular mortality and non-fatal myocardial infarction. 4

• The 2016 ESC/EAS guidelines classified patients with documented CVD as "very high risk" and recommended LDL-C <70 mg/dL (1.8 mmol/L), but this has been superseded by the more aggressive <55 mg/dL target in recent updates. 1

Even Lower Targets for Recurrent Events

• For patients who experience a second vascular event within 2 years while on maximally tolerated statin therapy, consider an LDL-C target of <40 mg/dL (1.0 mmol/L). 1, 4

• This represents a Class IIb, Level B recommendation for those with recurrent atherothrombotic events despite optimal therapy. 1

Treatment Algorithm to Achieve Target

Step 1: High-Intensity Statin Before Discharge

• Initiate high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) before hospital discharge in all CAD patients. 1, 2, 4

• High-intensity statins reduce LDL-C by ≥50% and lower major vascular events by approximately 15% compared to moderate-intensity statins. 1, 2

• This is a Class I, Level A recommendation across all major guidelines. 1, 2

Step 2: Reassess at 4-8 Weeks

• Re-measure lipid panel 4-8 weeks after discharge or any medication change to guide further therapy. 2, 4

Step 3: LDL-C-Guided Escalation

If LDL-C <55 mg/dL on maximally tolerated statin:

• Continue high-intensity statin without de-escalation, even if LDL-C falls to very low levels (<25 mg/dL). 1, 2, 3

• No safety concerns exist for achieving very low LDL-C concentrations. 2, 3

If LDL-C 55-69 mg/dL on maximally tolerated statin:

• Add ezetimibe 10 mg daily (Class IIa, Level B-R recommendation). 2, 4

• Ezetimibe provides an additional 15-25% LDL-C reduction. 2, 4

If LDL-C ≥70 mg/dL on maximally tolerated statin:

• Add ezetimibe 10 mg daily immediately (Class I, Level A recommendation). 1, 2, 4

• The IMPROVE-IT trial demonstrated that statin plus ezetimibe produced a 6.4% relative risk reduction in major cardiovascular events compared to statin alone. 1, 4

If LDL-C ≥70 mg/dL despite statin + ezetimibe:

• Add a PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) after clinician-patient discussion of net benefit, safety, and cost (Class I, Level A recommendation). 1, 2, 4

• PCSK9 inhibitors lower LDL-C by an additional 50-60% and reduce major adverse cardiovascular events by approximately 15% over 2-3 years. 1, 2, 4

• Patients treated closer to their ACS event experience greater absolute cardiovascular benefit from PCSK9 inhibitors. 2, 4

Management of Statin-Intolerant Patients

• For confirmed statin-intolerant patients, initiate bempedoic acid 180 mg plus ezetimibe 10 mg daily immediately (Class I, Level B-R recommendation). 2, 4

• Confirm true complete statin intolerance by objectively testing at least two different statins (including one at the lowest approved dose); true complete intolerance occurs in <3% of patients. 2, 4

• The CLEAR Outcomes trial demonstrated that bempedoic acid reduced major adverse cardiovascular events by 13% in statin-intolerant patients. 2

• The bempedoic acid/ezetimibe combination achieves approximately 35% LDL-C reduction. 2, 4

Upfront Combination Therapy Consideration

• The 2025 ACC/AHA guidelines introduce a Class IIb recommendation: concurrent initiation of ezetimibe with maximally tolerated statin may be considered at discharge in ACS patients. 2

• The 2024 International Lipid Expert Panel recommends immediate initiation of high-intensity statin plus ezetimibe for extremely high-risk patients rather than stepwise escalation. 2

Critical Safety Monitoring

• Monitor serum uric acid and watch for gout when prescribing bempedoic acid. 2

• Check liver function tests periodically in patients on bempedoic acid. 2

• Do not de-escalate statin intensity during follow-up in patients who tolerate treatment, regardless of how low LDL-C falls. 1, 2, 4

Common Pitfalls to Avoid

• Only approximately 22% of very high-risk secondary prevention patients in Europe achieve LDL-C <55 mg/dL, and another 22% receive no lipid-lowering therapy at all. 2

• Approximately 20% of ACS patients experience a recurrent cardiovascular event within 24 months, underscoring the need for aggressive early LDL-C lowering. 2

• Do not accept suboptimal LDL-C levels—escalate therapy aggressively rather than waiting for recurrent events. 2

• Starting statin therapy before hospital discharge markedly increases the likelihood that patients will remain on therapy and achieve LDL-C targets compared with initiating treatment after discharge. 2

Divergent Evidence on LDL-C Thresholds

• A 2023 Japanese randomized trial (REAL-CAD subanalysis) suggested that cardiovascular risk decreased monotonically until LDL-C reached 70 mg/dL, but when reduced further, the risk became independent of LDL-C level. 5

• However, this finding contradicts the preponderance of guideline evidence and multiple large randomized trials showing continued benefit at LDL-C levels well below 70 mg/dL, including down to 25 mg/dL. 2, 3, 6

• The weight of current guideline evidence from ESC, ACC/AHA, and International Lipid Expert Panel strongly supports the <55 mg/dL target based on Class I, Level A recommendations. 1, 2, 3